Adventure Time has crashed into Fortnite, bringing nostalgia and exciting characters to the game. Here are all the skins and how to get them.

It features a massive open world that favours blind exploration over hand-holding, puzzle chambers that grant upgrades, a cel-shaded aesthetic, and environment-manipulating powers. There are even ...

With limited exceptions, your inventory, currencies, and the manor all reset completely once each day ends. Blue Prince has a pleasing cel-shaded aesthetic to it, plus a ...

The therapy is known as chimeric antigen receptor T cell therapy, or CAR T cell therapy, where a patient's immune cells are taken out, grown and modified to specifically target certain cancers ...

Abstract: This article proposes an improved online electrochemical impedance spectroscopy (EIS) measurement strategy for fuel cell electric vehicle (FCEV) applications. A two-phase interleaved boost ...

[Looking ahead to our coverage next issue] the European Hematology Association/ European Bone Marrow Transplant 7th Chimeric Antigen Receptor (CAR) T-Cell Meeting provides the frontier for ...

Remplir is a collagen wrap used in nerve repair surgery to help surgeons fix ... Meanwhile in the large caps space, Amotiv (ASX:AOV), a car accessories manufacturer, saw its share price drop by 16% as ...

Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T, Novartis’ Kymriah (tisagenlecleucel), was approved ...

Moment reckless drink driver is caught on his own dash cam crashing his car into a tree after a night of booze - and plotting to falsely report it stolen. Charlie Taylor, 22, lost control of his ...

Credit: Vshivkova via Shutterstock. Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T, Novartis’ Kymriah ...

Credit: Juan Gaertner via Shutterstock. Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T, Novartis’s ...